Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 5c ; Offers Guidance

Amneal Pharmaceuticals (: AMRX) reported Q4 EPS of $0.14, $0.05 better than the analyst estimate of $0.09. Revenue for the quarter came in at $617 million versus the consensus estimate of $634.89 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2024 EPS of $0.53-$0.63, versus the consensus of $0.59. Amneal Pharmaceuticals sees FY2024 revenue of $2.55-2.65 billion, versus the consensus of $2.58 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Amneal gets FDA approval for lanreotide injection, launches immediately
• Corpay agrees to $100M FTC settlement over marketing practices
• Nucor projects Q3 2026 earnings above prior year, below estimates